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Mitochondrial electron transport generates the ATP that is essential for the excitability and survival of neu-
rons, and the protein phosphorylation reactions that mediate synaptic signaling and related long-term
changes in neuronal structure and function. Mitochondria are highly dynamic organelles that divide, fuse,
and move purposefully within axons and dendrites. Major functions of mitochondria in neurons include the
regulation of Ca2+ and redox signaling, developmental and synaptic plasticity, and the arbitration of cell sur-
vival and death. The importance of mitochondria in neurons is evident in the neurological phenotypes in rare
diseases caused by mutations in mitochondrial genes. Mitochondria-mediated oxidative stress, perturbed
Ca2+ homeostasis, and apoptosis may also contribute to the pathogenesis of prominent neurological dis-
eases including Alzheimer’s, Parkinson’s, and Huntington’s diseases; stroke; amyotrophic lateral sclerosis;
and psychiatric disorders. Advances in understanding the molecular and cell biology of mitochondria are
leading to novel approaches for the prevention and treatment of neurological disorders.
The Structure and Regulatory Systems of Mitochondria
More than 1 billion years ago, a primitive bacteria invaded a sin-
gle-cell anaerobic organism and, rather than killing the cell, es-
tablished a symbiotic relationship which has been maintained
and refined during the subsequent evolution of complex multi-
cellular organisms (Dyall et al., 2004). Mitochondria, the descen-
dants of the original symbiont, are organelles highly efficient in
their ability to utilize O2 and substrates such as glucose and py-
ruvate to produce cellular energy in the form of ATP (Wallace,
2005). Mitochondria consist of two membranes, an intermem-
brane space and an internal ‘‘matrix.’’ The molecular machinery
for energy production, the electron transport chain (ETC), is or-
ganized in an assembly line-likemanner within and across the in-
ner mitochondrial membrane (Figure 1). The ETC consists of five
protein complexes. Three of the complexes (I, III, and IV) pump
protons (H+) outwardly across the inner membrane to establish
a H+ gradient necessary for the production of ATP at complex
V (ATP synthase). Thirteen of the proteins of the ETC are en-
coded by genes in the mitochondrial genome. The remaining
proteins in mitochondria (more than 1000) are encoded by genes
in the cell nucleus and mediate processes such as the regulation
of ion homeostasis, stress responses, cell survival, and signal
transduction. The activity of complex I converts NADH to the
energy substrate NAD+ and complex II converts succinate to fu-
marate. During electron transport, O2 is converted to H2O and,
particularly at complexes I and III, the free radical superoxide
(O2
$) is also generated. Two important cofactors that modulate
energy and free radical production are coenzymeQ10 at complex
III and cytochrome c at complex IV.
Much of the O2
$ generated during mitochondrial respiration
is converted to hydrogen peroxide in a reaction catalyzed by
manganese superoxide dismutase (MnSOD). Hydrogen perox-
ide is, in turn, converted to water by glutathione peroxidase
and catalase. However, by reacting with Fe2+ or Cu+, hydrogen
peroxide generates the highly reactive hydroxyl radical (OH$),
which can induce membrane lipid peroxidation and damage
proteins and DNA. To further guard against oxidative damage,
mitochondria contain several prominent antioxidant molecules
including coenzyme Q10 (ubiquinone), creatine, and nicotin-
amide (Beal, 2003). Another reaction of interest from the view-
points of neuronal signaling and degeneration involves the
interaction of nitric oxide with O2
$ to produce peroxynitrite
(ONOO), a reactive molecule that can induce nitration of pro-
teins on tyrosine residues, thereby impairing the function of
those proteins (Goldstein and Merenyi, 2008). Free radicals are
also generated by the activity of mitochondrial monoamine oxi-
dases (MAOA and MAOB), enzymes involved in the metabolism
of serotonin, norepinphrine, and dopamine. Aside from their
potential to inflict damage, mitochondria-derived O2
$ and
hydrogen peroxide serve important signaling functions in physi-
ological processes including synaptic plasticity and learning and
memory (Kishida and Klann, 2007; Wang et al., 2008). The mem-
brane potential maintained by the H+ gradient, and several other
properties of mitochondria, can be evaluated in living neurons
using technologies described in Figure S1 (available online).
While the ability of mitochondria to remove Ca2+ from the cy-
toplasm and accumulate it in their matrix is well known, mito-
chondria also play roles in the regulation of rapid changes of
intracellular Ca2+ dynamics, and participate in many Ca2+-medi-
ated signaling processes (for review see Nicholls et al., 2003;
Giacomello et al., 2007). The functional properties of Ca2+ trans-
porters and channels in mitochondria are being characterized,
although in most cases the identities of the proteins that com-
prise the Ca2+-handling systems are unknown. The outer mito-
chondrial membrane is relatively permeable to Ca2+ and the in-
ner membrane contains key Ca2+-regulating proteins including
a Ca2+ uniporter that transfers Ca2+ into the mitochondrial matrix
and Na+/Ca2+ and H+/Ca2+ antiporters that move Ca2+ out of
the mitochondria (Figure 1). Thus, gradients of Ca2+, H+, and
Na+ concentrations greatly influence Ca2+ flux across the inner748 Neuron 60, December 11, 2008 ª2008 Elsevier Inc.
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located immediately adjacent to the endoplasmic reticulum
(ER) where they rapidly remove Ca2+ released into the cytoplasm
from the ER through activated inositol triphosphate (IP3) recep-
tors and ryanodine receptors (Figure 1). In this article we de-
scribe mitochondrial proteins involved in neuronal plasticity
and disease processes.
Mitochondrial Dynamics
Mitochondria function within an integrated reticulum that is con-
tinuously remodeled by growth and fission of individual mito-
chondria and the fusion of different mitochondria (Figure 2).
Key molecular mechanisms involved in mitochondrial fission
and fusion have recently been elucidated (see Berman et al.,
2008 for review). Before dividing, mitochondria replicate their
DNA, and levels of mitochondrial proteins encoded by nuclear
DNA increase in a process called biogenesis (described in Fig-
ure S2). Mitochondrial fission is mediated by two key proteins,
dynamin-related protein 1 (Drp1) and Fis1. Drp1 is located in
the cytoplasm and in punctate arrays on mitochondrial tubules,
and includes a GTPase domain and a GTPase effector domain.
Fis1 is located throughout the outer mitochondrial membrane,
with the bulk of the protein consisting of six antiparallel helices
(with the central four helices consisting of two tandem tetratrico-
peptide repeats) on the cytosolic side of the membrane. Addi-
tional proteins implicated in mitochondrial fission include endo-
philin B1 and MTP18. Endophilin B1 is a fatty acyl transferase
that is required for maintenance of mitochondrial morphology.
Knockdown of endophilin B1 causes the formation of vesicles
and tubules of outer mitochondrial membrane, and knockdown
of both endophilin B1 and Drp1 leads to a mitochondrial pheno-
type identical to that of the Drp1 single knockdown, suggesting
that endophilin B1 functions upstream of Drp1 in the process of
mitochondrial fission (Karbowski et al., 2004). Fission of mito-
chondria involves the recruitment of Drp1 (from remote cytosolic
and mitochondrial sites) to discrete foci within the mitochondria,
the sites where fission is initiated. MTP18 is a mitochondrial
membrane protein that, when overexpressed, increases mito-
chondrial fission, and when knocked down, increases fusion
(Tondera et al., 2005). Overexpression of Fis1 does not induce
mitochondrial fission in cells lacking MTP18, indicating that
MTP18 is required for mitochondrial fission. The nature of the
interactions between the different proteins that mediate mito-
chondrial fission, and how they induce the separation of the mi-
tochondrial membranes, remains to be established. However, it
has been suggested that Drp1 functions as a ‘‘mechanoenzyme’’
that uses GTP hydrolysis to induce constriction at mitochondrial
fission sites (Shaw and Nunnari, 2002).
Mitochondrial fusion is mediated by proteins called mitofusins
(Mfn1 andMfn2). Mfn1 andMfn2 are integral membrane proteins
located in the outer mitochondrial membrane with both the
C- and N-terminal regions protruding into the cytosol (Koshiba
et al., 2004). The N-terminal region contains a GTPase domain
and a hydrophobic heptad repeat region, and the C-terminal re-
gion also contains a heptad repeat region which may facilitate
homomeric binding and fusion of membranes of interacting mi-
tochondria. Mutations in Mfn2 cause Charcot-Marie-Tooth dis-
ease (CMT) type 2A, a peripheral neuropathy characterized by
Figure 1. Proteins Involved in Mitochondrial
Bioenergetics, Oxygen Radical Metabolism,
and Ca2+ Regulation
The electron transport chain (ETC) consists of four protein
complexes (I–IV) and the ATP synthase (complex V) lo-
cated in the mitochondrial inner membrane. The activity
of complex I converts NADH to NAD+, and the activity of
complex II converts succinate to fumarate. Complexes I,
III, and IV transport protons (H+) across the membrane,
and complexes I and III generate superoxide anion radical
(O2
$) during the electron transfer process. The enzymatic
activity of mitochondrial manganese superoxide dismu-
tase (MnSOD) converts O2
$ to hydrogen peroxide (H2O2),
which may then diffuse to the cytoplasmic compartments
where glutathione peroxidase and catalase convert H2O2
to H2O. However, H2O2 can interact with Fe
2+ or Cu+ to
generate hydroxyl radical (OH$), a highly reactive free rad-
ical that can induce lipid peroxidation and oxidative dam-
age to proteins and DNA. Mitochondrial uncoupling pro-
teins (UCP) function as H+ leak channels that decrease
mitochondrial membrane potential, resulting in decreased
generation of O2
$ and ATP. Several mitochondrial pro-
teins are involved in regulating movement of Ca2+ into
and out of the mitochondria, including the Ca2+ uniporter
which moves Ca2+ into the mitochondrial matrix, and the
Ca2+ antiporter which extrudes Ca2+ into the cytosol. In
addition, movement of K+ through ATP-sensitive potas-
sium channels (KATP) in the inner membrane can result
in decreased mitochondrial Ca2+ uptake. An important
transmembrane protein complex that includes the volt-
age-dependent anion channel (VDAC) forms large perme-
ability transition pores (PTP). The PTP open during the process of apoptosis, resulting in the release of cytochrome c into the cytoplasm. Several cytoplasmic
proteins, including Bcl-2 and BH-only proteins such as Bax, Bid, and Bik, may also interact with mitochondrial membranes, resulting in a change in their perme-
ability. Finally, there are interactions between mitochondria and the endoplasmic reticulum (ER) such that Ca2+ released through ER IP3 receptors and ryanodine
receptors (RyR) is rapidly transferred intomitochondria. On the other hand, cytochrome c released frommitochondria can trigger the release of Ca2+ from the ER.Neuron 60, December 11, 2008 ª2008 Elsevier Inc. 749
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tochondrial fusion defect caused by mutant Mfn2 but, interest-
ingly, wild-type Mfn1 can overcome the pathological effect of
mutant Mfn2 (Detmer and Chan, 2007). Another protein critical
for mitochondrial fusion is optic atrophy 1 (OPA1), a member of
the dynamin family of GTPases located in the mitochondrial
intermembrane space where it is associated with the inner
membrane.
Fusion can occur rapidly (within less than 1 min), and the un-
derlying events must therefore involve the coordinated fusion
of the outer and inner mitochondrial membranes. A simplified
model therefore involves outer membrane fusion mediated by
homotypic (Mfn1-Mfn1 or Mfn2-Mfn2) or heterotypic (Mfn1-
Mfn2) binding of mitofusins in trans, followed by OPA1-mediated
fusion of the inner membranes (Figure 2). Mitochondrial fusion
requires the proton gradient generated by a functioning ETC
and, therefore, metabolically compromised mitochondria are
fusion incompetent. Mitochondrial fission often occurs soon
after two mitochondria fuse. Immediately following fusion mito-
chondrial contents are segregated so as to enrich one of the
mitochondria generated by subsequent fission with well-func-
tioning components while targeting the impoverished fission
partner for autophagic degradation (Twig et al., 2008); in this
way cells are able to retain healthy mitochondria during the life-
time of the organism. Another possible function of mitochondrial
fission is to generate variability in mitochondrial phenotypes
which are then deployed to different regions of the cell or re-
spond to different environmental demands.
Because of highly complex neuronal morphologies that in-
clude long axons and elaborate dendritic arbors, it is essential
that mechanisms exist to transport mitochondria throughout
the neuron, and to recruit mitochondria to regions with particu-
larly high metabolic demands such as presynaptic terminals
(Hollenbeck and Saxton, 2005). Mitochondrial transport occurs
by microtubule motor-driven translocation along microtubule
tracks that are arranged in polarized parallel arrays. Mitochon-
dria can be actively transported in both the anterograde and
retrograde directions by ATP-dependent ‘‘motor’’ proteins (Fig-
ure 3). Anterograde transport is mediated by kinesins, while
dynein motor proteins mediate retrograde transport. Mitochon-
dria do not bind directly to the motor proteins but, instead,
bind to adaptor proteins that link the mitochondrial membrane
to the motor protein. Milton, syntabulin, and Miro are adaptor
Figure 2. Mitochondrial Fusion and Fission Mechanisms
Mitochondria can fuse with each other and exchange their membrane, inter-
membrane, and matrix components (upper left). Fusion of the outer mitochon-
drial membranes is mediated by homophilic and heterophilic interactions of
cytosolic domains of mitofusins (Mfn1 and Mfn2), which are proteins located
in the outer mitochondrial membrane (upper right). Fusion of the inner mito-
chondrial membranes is believed to be mediated by OPA1, which is located
in the intermembrane space. Mitochondrial fission (lower left) involves recruit-
ment of dynamin-related protein 1 (Drp1) to discrete foci within the mitochon-
dria, and also requires Fis1, a protein located in the outer mitochondrial mem-
brane (lower right).
Figure 3. Mitochondrial Trafficking Mechanisms
within the Axon
Microtubules serve as tracks along which mitochondria
move either toward the presynaptic terminal (anterograde
transport) or toward the cell body (retrograde transport).
ATP-dependent motor proteins that move mitochondria
along microtubules include kinesins (anterograde) and dy-
nein (retrograde). Mitochondria associate with the motor
proteins through specific adaptor proteins (AP). AP for
kinesins include Milton, syntabulin, and a Rho GTPase
calledMiro. Dynactin is an AP for dynein. Within the axonal
growth cone and presynaptic terminal, mitochondria may
be anchored and moved along actin filaments by a myo-
sin-mediated mechanism.750 Neuron 60, December 11, 2008 ª2008 Elsevier Inc.
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nein (Rice and Gelfand, 2006; Frederick and Shaw, 2007). While
progress has been made in identifying the proteins involved in
mitochondrial transport within neurons, the signaling mecha-
nisms that control mitochondrial transport in response to local
changes in neuronal activity and energy metabolism are largely
unknown. For example, what is the mechanism that couples
mitochondrial membrane potential to transport such that
mitochondria with a greater membrane potential undergo
anterograde transport, whereas mitochondria with a low mem-
brane potential undergo retrograde transport (Miller and Sheetz,
2004)?
It is likely that neurotransmitters and neurotrophic factors con-
trol mitochondrial dynamics because of their influences on neu-
ronal energy metabolism, Ca2+ homeostasis, and dendritic and
axonal motility. Indeed, a recent study showed that cerebellar
Purkinje cells in mice deficient in the glutamate receptor Grid2
exhibit extremely long mitochondria, abnormal spines and syn-
apses, and severe ataxia, providing evidence that glutamate re-
ceptor-mediated signaling affects mitochondrial fission and/or
fusion (Liu and Shio, 2008). Further studies in which the effects
of neurotransmitters and neurotrophic factors on the molecular
machineries that regulate mitochondrial fission, fusion, and
movement within neurons will expand our appreciation of the in-
tegration of mitochondrial motility with neuronal functional and
structural dynamics.
Developmental Roles for Mitochondria
During development of the nervous system, neural stem cells
proliferate and then differentiate into neurons in the process of
neurogenesis. The newborn neurons then grow an axon and
dendrites and eventually form synapses; during this process
many newly generated neurons undergo programmed cell death
(PCD) (apoptosis). What are the roles of mitochondria in these
highly complex and dynamic developmental events? Changes
in mitochondrial energy metabolism occur in brain cells during
embryonic and early postnatal development with a shift from
the use of fatty acids as fuels during early development to the
use of glucose later on (Erecinska et al., 2004), suggesting roles
for mitochondria in supporting the different bioenergetic require-
ments of highly proliferative neural stem cells and postmitotic
neurons. During neuronal differentiation the number of mito-
chondria per cell increases, but the velocity at which individual
mitochondria move decreases as neurite outgrowth slows and
synaptogenesis occurs (Chang and Reynolds, 2006). Treatment
with chloramphenicol (an inhibitor of mitochondrial protein syn-
thesis) prevents differentiation of the cells, whereas oligomycin
(an inhibitor of the mitochondrial ATP synthase) does not, sug-
gesting that increased mitochondrial mass (but not ATP produc-
tion) is required for neuronal differentiation (Vayssie`re et al.,
1992). In addition, signals that influence mitochondrial biogene-
sis and function, including nitric oxide (Barsoum et al., 2006) and
BDNF (Markham et al., 2004), may regulate the proliferation
and differentiation of neural progenitor cells in the developing
and adult brain (Cheng et al., 2003).
Soon after differentiating from stem cells, neurons extend sev-
eral neurites, one of which begins to grow rapidly and acquires
the molecular, structural, and functional characteristics of the
axon, while the other neurites become dendrites. Shortly before
axogenesis occurs mitochondria congregate at the base of the
neurite that is destined to become the axon (Mattson and Partin,
1999), and during axogenesis there is increased entry of mito-
chondria into the nascent axon while the mitochondrial density
in the remaining short processes (dendrites) decreases (Ruthel
and Hollenbeck, 2003).
When electron transport is impaired (by selectively damaging
mitochondrial DNA) and the cells are provided an alternative en-
ergy source to maintain ATP levels, axogenesis is abolished, but
growth of dendrites is relatively unaffected (Mattson and Partin,
1999). Mitochondria may play a key role in establishing neuronal
polarity by reducing the Ca2+ concentration at the base of pre-
sumptive axon, thereby promoting polymerization of microtu-
bules and the rapid growth and differentiation of the axon.
After axons and dendrites differentiate, their growth and syn-
aptic connectivity may be influenced by mitochondrial motility
and functions. During the formation of axonal branches mito-
chondria respond to changes in growth by modifying their entry
into branches; however, the latter process does not require an
active growth cone, suggesting the involvement of a mechanism
different from that by which mitochondria accumulate in the
growth cone (Ruthel and Hollenbeck, 2003). Focal application
of nerve growth factor (NGF) to growing axons results in the
accumulation of mitochondria near the site of NGF stimulation
by a mechanism involving docking interactions with the actin
cytoskeleton, suggesting a role for mitochondria in facilitating
growth cone responses to neurotrophic factors (Chada and
Hollenbeck, 2004).
Many newly generated neurons undergo PCD, a process reg-
ulated by neurotrophic factors and controlled by mitochondria
(Kirkland and Franklin, 2003). Changes in the levels of expression
of Bcl-2 family members that regulate mitochondria-mediated
cell death occur during the processes of neurogenesis and
neuronal differentiation. For example, in the developing mouse
brain, levels of antiapoptotic Bcl-xL are highest at the peak of
neurogenesis, whereas the peak of proapoptotic Bax expression
coincides with astrocyte production (Chang et al., 2007). Inter-
estingly, overexpression of Bcl-xL and Bax in neural progenitors
induces neuronal and astrocytic differentiation, respectively, and
these roles of Bcl-xL and Bax are apparently independent of their
effects on cell survival and death (Chang et al., 2007).
To date, the evidence that mitochondria play important roles in
sculpting cytoarchitecture during development of nervous sys-
tems is based largely on correlational data—the location or prop-
erties of mitochondria change in association with developmental
processes. Several approaches could be employed to establish
the function of mitochondria in development, including the fol-
lowing: knocking down mitochondrial function globally under
conditions where cellular energy levels are maintained (low-
dose ethidium bromide together with pyruvate and uridine
supplementation); knocking down the expression or function of
proteins involved in specific mitochondrial processes (Ca2+
regulation, reactive oxygen species [ROS] metabolism, fission,
fussion, permeability transition pore [PTP] function, etc.); and
targeted inhibition of mitochondrial motility and functions selec-
tively in subcellular regions (only in dendrites, axons, or synap-
ses). Time-lapse analysis of mitochondrial movements withinNeuron 60, December 11, 2008 ª2008 Elsevier Inc. 751
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(electrical activity, activation of neurotrophic factor receptors,
cell adhesion cues, etc.) will elucidate potential roles of mito-
chondria in plasticity. Selective ablation and artificial movement
of mitochondria (using two-photon laser technology, for exam-
ple) may establish the requirements of mitochondria for specific
physiological events (neurite outgrowth, dendritic remodeling,
etc.).
Mitochondria in Synaptic Plasticity
Mitochondria presumably produce much of the ATP required to
maintain synaptic ion homeostasis and phosphorylation reac-
tions, and indeed, presynaptic terminals typically contain multi-
ple mitochondria (Figures 3 and 4). Dendritic spines of excitatory
glutamatergic synapses, the most abundant type of synapse in
the mammalian CNS, experience large amounts of Ca2+ influx
through N-methyl-D-aspartate (NMDA) receptors and voltage-
dependent Ca2+ channels (VDCC), as well as release of Ca2+
from the ER (Toresson and Grant, 2005). Dendrites also contain
Figure 4. Roles of Mitochondria in Developmental
and Synaptic Plasticity
(A) Mitochondria play a pivotal role in axogenesis. At the time of
plating in cell culture, embryonic rat hippocampal neurons were
not (control) or were (Mito-) treated with ethidium bromide, which
damages mitochondrial DNA and thereby renders the ETC dys-
functional. Images show neurons approximately 4 days later; the
neurons in the control culture elaborated long axons (arrows)
and shorter dendrites, whereas the Mito- neurons formed only
shorter processes and no axons. Scale bar, 10 mm.
(B) Electron microscopic image of synapses in the adult rodent
brain showing a dendritic spine with three postsynaptic densities
(psd), two presynaptic terminals with numerous synaptic vesicles
(v), and a mitochondrion (mit) in one presynaptic terminal.
(C) Involvement of mitochondrial motility in synaptic plasticity. This
example shows a neuron receiving synaptic inputs onto two den-
dritic spines. Activation of Input 1 results in Ca2+ influx into the
dendritic spine, which induces the local engagement of cytoskel-
eton-mitochondria interactions and thus results in the transloca-
tion of a mitochondrion to the base of that spine. In contrast,
mitochondria are not recruited to an adjacent inactive synapse
(Input 2). Mitochondrial transport along axons and dendrites
may also be influenced by action potentials. By moving to regions
of active synapses, mitochondria may contribute to plasticity by
increasing the local supply of ATP and by buffering and releasing
Ca2+.
mitochondria, although they are typically absent from
spines (Figure 4C). One exception is olfactory bulb
dendritic spines, which subserve both presynaptic
and postsynaptic functions, and which contain mito-
chondria that can move back and forth between
spines and the parent dendrite (Cameron et al.,
1991). The behaviors and functional properties ofmito-
chondria differ in axons and dendrites. For example,
twice as many mitochondria are motile in the axons
as compared with the dendrites of cultured hippocam-
pal neurons, and there is a greater proportion of highly
charged, more metabolically active mitochondria in
dendrites than in axons (Overly et al., 1996).
Synapses that are very active become potentiated,
resulting in long-term increases in the size and func-
tional ‘‘strength’’ of those synapses, which are forms
of synaptic plasticity implicated in learning and memory (Harms
et al., 2008). Recent findings in which the motility and function of
mitochondria have been visualized in experimental models sug-
gest that mitochondria play active roles in synaptic plasticity.
During synaptogenesis the movement of mitochondria into den-
dritic protrusions correlates with the morphological plasticity of
developing spines; impairment of the dynamin-like GTPases
Drp1 and OPA1 reduces dendritic mitochondria content and
causes a loss of synapses and dendritic spines, whereas in-
creasing dendritic mitochondrial content enhances the number
and plasticity of spines and synapses (Li et al., 2004). Genetic
manipulations of syntaphilin have revealed a role for this protein
as a negative regulator of mitochondrial motility in axons; synta-
philin mutant neurons exhibit enhanced short-term facilitation
during prolonged stimulation, probably by affecting mitochon-
dria-mediated Ca2+ signaling at presynaptic terminals (Kang
et al., 2008).Moreover, inDrosophilaMilton interacts with kinesin
and is required for transport of mitochondria to presynaptic
terminals; photoreceptors mutant for Milton show aberrant752 Neuron 60, December 11, 2008 ª2008 Elsevier Inc.
Neuron
Reviewsynaptic transmission despite normal phototransduction (Stow-
ers et al., 2002). It remains to be established if and how recruit-
ment of mitochondria to active synapses contributes to long-
term changes in synaptic strength.
In addition to movements of mitochondria within axons and
dendrites, changes in mitochondrial functions (Ca2+ regulation,
energy metabolism, and oxyradical production) also play roles
in synaptic plasticity. Posttetanic potentiation, a form of plastic-
ity that arises from a persistent presynaptic Ca2+ elevation
following tetanic stimulation, is blocked by inhibitors of mito-
chondrial Ca2+ uptake and release (Tang and Zucker, 1997).
Blocking the posttetanic potentiation with cyclosporin A results
in an increase of basal synaptic transmission and impairs synap-
tic plasticity (Levy et al., 2003). Other findings suggest that pre-
synaptic mitochondria play a role in the maintenance of synaptic
transmission by sequestering Ca2+ and thereby accelerating re-
covery from synaptic transmission during periods of moderate to
high synaptic activity (Billups and Forsythe, 2002). Neurons in
Drosophila Drp1 mutants exhibit synapses devoid of mitochon-
dria and elevations in resting Ca2+ levels at neuromuscular junc-
tions (Verstreken et al., 2005). Basal synaptic transmission is
largely normal in Drp1 mutant flies, but during intense stimula-
tion, mutants fail to maintain normal neurotransmission. Al-
though exocytosis and endocytosis are normal in the mutants,
the ability tomobilize reserve pool vesicles is impaired as a result
of reduced ATP availability. Moreover, age-related cognitive im-
pairment, and presumably the synaptic plasticity subserving
learning andmemory, is associated with structural abnormalities
inmitochondria and oxidation of RNA andDNA (Liu et al., 2002a).
Emerging findings suggest roles for mitochondria as media-
tors of at least some of the effects of glutamate and BDNF on
synaptic plasticity. An increasing number of signaling functions
for mitochondria are being discovered (Figure S3). For example,
glutamate-receptor-mediated patterned synaptic activity, such
as occurs during stimulus-train-induced bursting, results in
slow and prolonged changes in mitochondrial potential that ex-
hibit both temporal and spatial correlations with the intensity of
the electrical activity (Bindokas et al., 1998). The patterned
changes in mitochondrial membrane potential involve gluta-
mate-receptor-mediated Ca2+ influx. Synaptic activation of glu-
tamate receptors may also affect mitochondrial bioenergetics
independently of Ca2+ influx, as suggested by studies of stimu-
lus-evoked changes in NAD(P)H fluorescence at CA1 synapses
in hippocampal slices (Shuttleworth et al., 2003). Several neuro-
trophic factors, including BDNF, which plays a pivotal role in hip-
pocampus-dependent learning and memory (Lu et al., 2008),
have been shown to modify synaptic plasticity. BDNF promotes
synapticplasticity in part byenhancingmitochondrial energypro-
duction because it increases glucose utilization in cultured corti-
cal neurons in response to enhanced energy demand (Burkhalter
et al., 2003) and increases mitochondrial respiratory coupling at
complex I (Markham et al., 2004). Consistent with this possibility,
BDNF expression and signaling is increased in response to envi-
ronmental factors such as exercise and cognitive stimulation that
increase cellular energy demand (Mattson et al., 2004).
Many questions concerning the roles of mitochondria in syn-
aptic plasticity remain unanswered. Are mitochondria in presyn-
aptic terminals phenotypically different from those in dendrites?
How does synaptic activity affect mitochondrial function and
motility, assuming it does so? This could be determined by com-
bining manipulations of specific signaling components (gluta-
mate receptors, Ca2+-dependent kinases and other kinases,
cyclic nucleotides, nitric oxide, etc.) with high-resolution, imag-
ing-based measurements of mitochondrial motility and func-
tional status (membrane potential, ROS and Ca2+ levels, etc.).
Behavioral and electrophysiological evaluation of synaptic plas-
ticity in mice with a conditional knockdown of proteins with spe-
cific roles in mitochondrial motility (Drp1, Fis1, Mfn, and OPA)
and function (components of the mitochondrial ETC, PTP, and
Ca2+ handling systems, for example) should establish the roles
of these proteins in synaptic plasticity.
Pivotal Roles for Mitochondria in Neuronal Cell Death
Two general types of cell death are widely recognized—necrosis
and PCD (Figure S4). Necrosis is sometimes referred to as acci-
dental cell death, implying that cells do not execute preexisting
programs; instead, they are caught ‘‘off guard’’ in these situa-
tions. In PCD the cell ‘‘decides’’ to die and so activates a molec-
ular suicide cascade that involves the production and mobiliza-
tion of various proteins that can be considered as excecutioners.
Necrosis
Necrosis is not typical for developmental or tissue-turnover-
related cell death. Instead, neuronal necrosis occurs under con-
ditions of severe energy deprivation and oxidative and ionic
stress. A neuron undergoing necrosis dies rapidly as the result
of cell swelling, activation of proteases, and the rupture of cell
membranes (Figure S4B). During necrosis intracellular contents,
which contain neurotoxic substances such as glutamate and
lysosomal enzymes, are spewed into the extracellular space
(Nieminen, 2003). A typical trigger for necrosis is ATP depletion
caused by severe ischemia, glutamate toxicity, or mitochondrial
toxins. Moreover, apoptotic stimuli can cause necrosis when cy-
tosolic ATP is depleted because apoptosis requires ATP for its
execution. During necrosis mitochondria accumulate Ca2+, their
inner membrane becomes structurally disorganized and dam-
aged, and the mitochondria swell and may rupture. In some in-
stances, antagonists of ionotropic glutamate receptors or acti-
vated ATP-sensitive K+ channels can preserve mitochondrial
function and prevent necrosis (Rogawski, 1993; Liu et al.,
2002b). It may also be possible to protect neurons against necro-
sis by blocking pivotal enzymatic events, such as activation of
c-jun N-terminal kinase (JNK) (Arthur et al., 2007) and calpains
(Widdowson et al., 1997). The rapidity of the necrosis process
severely limits the ability of the cell to survive, therefore empha-
sizing the importance of preventing exposure to the necrotic in-
sult—eatingwell and exercising to reduce the chance of a stroke,
for example.
Programmed Cell Death
Apoptosis is the prototypical form of PCD in neurons during de-
velopment and adult cell turnover, and it may also occur in
a range of neurodegenerative conditions (see section on neuro-
logical disorders below). Morphologically it is characterized by
cell shrinkage, membrane blebbing, and karyorrhexis. On a
biochemical level two apoptotic cascades exist: an intrinsicNeuron 60, December 11, 2008 ª2008 Elsevier Inc. 753
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sic pathway that bypasses mitochondria (see Stefanis, 2005 for
review). The intrinsic pathway (Figure S4C), which predominates
in neurons, is initiated with a cell death signal such as trophic
factor withdrawal, moderate overactivation of glutamate recep-
tors, oxidative stress, and DNA damage. The apoptotic trigger
often activates kinases such as JNK and transcription factors
such as p53 that induce the expression and mitochondrial trans-
location of the proapoptotic Bcl-2 family members Bax and Bak,
which form pores in the outer mitochondrial membrane. The in-
creased permeability of the outer mitochondrial membrane also
involves the formation of a large multiprotein PTP through which
cytochrome c passes from the mitochondrial intermembrane
space to the cytosol. In the cytosol cytochrome c binds to apo-
ptosis protease activating factor 1 (Apaf-1) and ATP (or dATP) to
form the apoptosome, which then recruits and activates the ini-
tiator caspase 9 (Riedl and Salvesen, 2007). Caspase 9 then
cleaves and activates caspase 3 which, in turn, cleaves numer-
ous protein substrates that execute the cell death process.
There are several additional points of regulation of the apopto-
tic process. For example, Bax and Bak actions can be inhibited
by Bcl-2, BcL-xL, or other antiapoptotic members of the Bcl-2
family, and caspases can be inhibited by inhibitor of apoptosis
proteins (IAPs). IAPs on the other hand can be inhibited by the
mitochondrial protein secondary mitochondria-derived activator
of caspases (Smac/DIABLO) and high temperature requirement
protein A2 (HtrA2/Omi). Bax and Bak action can be enhanced/
initiated by proapoptotic members of the same family, most
importantly by caspase 3-cleaved (truncated) Bid (tBid). In the
nucleus caspase 3 activates caspase activated DNase (CAD)
(Enari et al., 1998), which cleaves nuclear DNAbetween histones,
creating DNA fragments of 160 bp or multiples thereof. Thus,
cytochrome c release, caspase 3 activation, and nucleosomal
DNA cleavage are three biochemical hallmarks of apoptosis.
While caspase inhibition can prevent cell death, it does not
prevent cytochrome c release into the cytosol, and may thereby
compromise mitochondrial ATP generation while simultaneously
increasing superoxide production. Consequently, caspase in-
hibiton can render neurons vulnerable to necrosis. Similarly,
apoptosis inducing factor (AIF) and HtrA2 are essential compo-
nents of mitochondrial structure and function, and their release
into the cytosol impairs mitochondrial function (Cheung et al.,
2006; Martins et al., 2004). Some evidence suggests that mito-
chondria can release cytochrome c, Smac, HtrA2, and AIF with
some degree of selectivity, but the mechanism is unclear (Huang
et al., 2001; Wang et al., 2004). Nevertheless, PCD is reduced in
mice deficient in Apaf-1(Yoshida et al., 1998), caspase 3 (Kuida
et al., 1996), or caspase 9 (Hakem et al., 1998), as well as in mice
in which cytochrome c is mutated so that it cannot activate cas-
pase 9 but still functions as an electron carrier (Hao et al., 2005).
The phenotype of each of the latter mice is characterized by
a lack of cell death in CNS precursor populations, resulting in
gross misdevelopment of the brain and either embryonic or early
postnatal death. Remarkably, caspase 3-deficient mice do not
have any overt phenotype when bred on a C57BL/6 genetic
background, in contrast to the cortical dysgenesis observed on
a mixed genetic background (Leonard et al., 2002); the reason
for this effect of genetic backgrounds is unknown.
In most cells Bax and Bak can compensate for each other;
however, in cultured cerebellar granule neurons and sympa-
thetic neurons, Bax deficiency alone very effectively inhibits tro-
phic-factor-withdrawal-induced apoptosis (Miller et al., 1997).
Bax deficiency does not prevent neuronal atrophy or downregu-
lation of cell metabolism, but rather prevents the execution of
apoptosis. Combined deficiency of Bax and Bak is very effective
in preventing outer mitochondrial membrane permeability and
apoptosis, resulting in CNS dysgenesis (Lindsten et al., 2000).
In contrast, Bid-deficient mice survive into adulthood without
obvious developmental abnormalities (Yin et al., 1999), yet their
neurons exhibit increased resistance to ischemic injury (Plesnila
et al., 2001). The proteins that form the PTP downstream of Bax,
Bak, and Bid interactions with the mitochondrial membrane, and
the mechanism of pore formation remains elusive. The long-
standing concept that the adenine nucleoside transporter
(ANT) and voltage-dependent anion channel (VDAC) constitute
the mitochondrial PTP has been recently challenged by the phe-
notypes of mice deficient in these proteins (see Juhaszova et al.,
2008 for review).
While apoptotic PCD involves the entire cell, apoptotic bio-
chemical cascades that involve mitochondria can be triggered
locally within dendrites and axons, where they may play roles
in neuritic and synaptic structural and functional plasticity. Acti-
vation of glutamate receptors in the dendrites of embryonic hip-
pocampal neurons results in a local increase of mitochondrial
membrane permeability and activation of caspase 3 in the den-
drites (Mattson et al., 1998). The latter study also showed that
exposure of isolated synapses to triggers of apoptosis results
in mitochondrial membrane depolarization, ROS production,
andCa2+ accumulation and activation of caspase 3. Prostate ap-
optosis response 4, a mediator of neuronal apoptosis that acts
upstream of mitochondrial alterations, can also be activated
locally in synapses (Duan et al., 1999). Other studies have shown
that inhibitors of caspases 1 and 3 can modify long-term poten-
tiation of synaptic transmission at hippocampal synapses
(Gulyaeva et al., 2003; Lu et al., 2006), suggesting roles for apo-
ptotic cascades in synaptic plasticity. Cleavage of theGluR1 and
GluR4 subunits of AMPA glutamate receptors by caspase 3 may
mediate some of the effects of the intrinsic apoptotic pathway on
synaptic plasticity, and may also provide a mechanism that (by
reducing Na+ and Ca2+ influx) prevents excitotoxic necrosis
(Glazner et al., 2000; Lu et al., 2002). A role for mitochondrial ap-
optotic cascades in synaptic remodeling in vivo is suggested by
the demonstration that caspase 3 activity increases transiently in
dendritic spines in auditory forebrain of the zebra finch in re-
sponse to exposure to tape-recorded birdsong (Huesmann
and Clayton, 2006). Selective blockade of caspase 3 impairs
consolidation of a persistent physiological trace of the song
stimulus, thus establishing a role for caspase 3 in learning and
memory.
In addition to their role in the most common caspase-medi-
ated form of PCD, mitochondria also mediate a different type
of neuronal death that is caspase independent (CIPCD) in which
the outer mitochondrial membrane becomes permeable, but in-
stead of cytochrome c, AIF is released (Figure S4D). CIPCD in
neurons has been most clearly demonstrated in cell death para-
digms in which activation of poly (ADP-ribose) polymerase754 Neuron 60, December 11, 2008 ª2008 Elsevier Inc.
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mers occurs (Yu et al., 2002, 2006). PARP-1 is an NAD+-depen-
dent enzyme that is activated in neurons by overactivation of
glutamate receptors and in response to DNA damage and is
required for AIF release from mitochondria. PAR polymers
associate withmitochondria and induce the release of AIF, which
then translocates to the nucleus and triggers nuclear DNA
fragmentation.
Despite the evidence that mitochondria are pivotal arbitrators
of neuronal cell survival and death decisions, critical issues re-
main unresolved. The identities of the proteins that mediate
key death-regulatory systems within mitochondria, such as
components of the PTP and ATP-sensitive K+ channels, are un-
known. In addition, the physiological roles of subthreshold levels
of activation of ‘‘death events’’ (PTP opening, cytochrome c re-
lease, Ca2+ uptake and release, etc.) remain to be established.
The evidence that the latter events can occur locally and tran-
siently in synaptic terminals, dendrites, and axons suggests
important roles in synaptic plasticity and neurite outgrowth. We
believe that future studies will reveal a range of nonapoptotic
functions for different caspases and other ‘‘apoptotic’’ proteins
(Bcl-2 and p53 familymembers and PARP-1, for example) in pro-
cesses ranging from neurogenesis to synaptic plasticity.
Neurological Disorders
Several inherited diseases are caused bymutations in mitochon-
drial DNA, and the cell types most affected in these disorders are
those with high energy demands, including muscle cells and
neurons (Wallace, 2005). However, the most common neurolog-
ical disorders (Alzheimer’s, Parkinson’s, and Huntington’s dis-
eases; stroke; and psychiatric disorders) are not caused by
mitochondrial mutations, but instead typically involve interac-
tions of nuclear genetic and environmental variables. In this
section we describe the current state of understanding of the
roles of mitochondria in the dysfunction and degeneration of
neurons in major neurological disorders.
Ischemic stroke
During a stroke the drastic reduction in blood supply to neurons
normally perfused by the affected cerebral blood vessel results
in cellular hypoxia and glucose deprivation, leading to greatly di-
minished ETC activity and ATP depletion (Moustafa and Baron,
2008). Histologically, the brain tissue affected by a stroke con-
sists of a core region where ischemia is severe and the neurons
die rapidly by necrosis, and a surrounding penumbra where the
neurons may die over a period of hours to several days by a PCD
mechanism or mechanisms. The involvement of mitochondria in
ischemic neuronal death in the penumbra is supported by con-
siderable data from experimental models (particularly middle ce-
rebral artery occlusion—reperfusion studies in rodents) reviewed
in detail elsewhere (Zheng et al., 2003) that include Ca2+ influx
through NMDA receptors and accumulation of Ca2+ in mitochon-
dria (Zhang and Lipton, 1999); mitochondrial O2
$ production
and consequent oxidative damage to proteins, lipids, and DNA
(Keller et al., 1998); p53-mediated Bax expression and facilita-
tion of PTP formation (Culmsee and Mattson, 2005; Endo
et al., 2006); and PTP opening, cytochrome c release, and acti-
vation of caspases 9 and 3 (Friberg et al., 1998; Korde et al.,
2007). In addition to Bax, Bid has been shown to be a pivotal pro-
moter of mitochondrial PTP formation and cytochrome c release
in neurons undergoing ischemic cell death (Plesnila et al., 2001).
Several putative components of the PTP have been implicated in
ischemic neuronal death including cyclophilin D (Schinzel et al.,
2005) and porin (Perez Velazquez et al., 2000). Recently a novel
protein called pancortin-2 was shown to promote mitochondria-
mediated apoptosis during cerebral ischemia by interacting with
the actin-associated protein WAVE1 and sequestering Bcl-xL,
thereby preventing Bcl-xL from stabilizing mitochondrial mem-
branes (Cheng et al., 2007). Interestingly, mitochondrial fission
occurs in neurons during ischemic conditions and may contrib-
ute to their death, because prevention of fission by knockdown
of Drp1 or overexpression of Mfn1 protects neurons against
hypoxic death (Barsoum et al., 2006).
Two additional classes of mitochondrial proteins that play im-
portant roles in protecting neurons against excitotoxic and is-
chemic injury are K+ channels and uncoupling proteins (UCPs).
Treatment with the mitochondrial K+ channel opener diazoxide
reduces mitochondrial Ca2+ uptake and oxidative stress, pre-
vents PTP formation, and protects neurons against excitotoxic
and ischemic injury (Liu et al., 2002b). Mitochondrial UCPs re-
duce mitochondrial oxyradical production by dissipating the H+
gradient across the inner mitochondrial membrane. Neurons in
transgenic mice overexpressing UCP-2 exhibit increased resis-
tance to death in models of focal ischemic stroke and traumatic
brain injury (Mattiasson et al., 2003). Studies of cultured neurons
in which UCP-4 levels were reduced using RNA interference
methods demonstrated roles for UCP-4 in modifying cellular
energy metabolism (decreasing ETC activity and increasing
glucose uptake and glycolysis) and reducing oxyradical produc-
tion in ways that increase the resistance of the neurons to exci-
totoxic and oxidative insults (Liu et al., 2006). UCP-4 activity
reduces mitochondrial Ca2+ accumulation and store-operated
Ca2+ entry, a process in which depletion of ER Ca2+ stores trig-
gers Ca2+ influx through plasmamembrane Ca2+ channels (Chan
et al., 2006).
Finally, studies of ischemic death have revealed roles for mito-
chondria in a process called preconditioning hormesis, in which
the expression of genes that encode cytoprotective proteins, in-
cluding chaperones such as heat-shock protein 70 (HSP-70) and
glucose-regulated protein 78 (GRP-78), antiapoptotic proteins
suchasBcl-2, andantioxidant enzymes, is increased (Arumugam
et al., 2006). Ischemic preconditioning hormesis has been shown
to block ischemia-induced translocation of BAD tomitochondria,
Bcl-xL cleavage, and PTP formation in mitochondria (Miyawaki
et al., 2008). Bcl-2 may protect neurons against excitotoxicity
and ischemic injury by enhancing the ability of mitochondria to
sequester large quantities of Ca2+ while their respiratory function
ismaintained (Murphyet al., 1996). Several therapeutic strategies
for stroke, including dietary energy restriction (Yu and Mattson,
1999) and mitochondrial uncouplers (Korde et al., 2005), may
act in part by inducing an adaptive mitochondrial stress re-
sponse. Thus, in addition to reducing risk factors such as hyper-
tension, a lifestyle that includes regular exposure to dietary and
behavioral factors that induce an adaptive cellular stress re-
sponse in neurons would be expected to improve the outcome
in individuals who do suffer a stroke (Mattson and Cheng, 2006).Neuron 60, December 11, 2008 ª2008 Elsevier Inc. 755
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Alzheimer’s disease (AD) affects nearly 5 million Americans, and
will soon become the second leading cause of death as more
people live into their seventh and eighth decades. AD involves
progressive synaptic dysfunction and then death of neurons in
brain regions critical for learning and memory processes (hippo-
campus, entorhinal and frontal cortices, and associated struc-
tures), and is characterized histopathologically by the accumula-
tion of extracellular plaques comprosed of amyloid b-peptide
(Ab) and intracellular neurofibrillary tangles that are aggregates
of the microtubule-associated protein tau (Goedert and Spillan-
tini, 2006). Proteolytic processing of the b-amyloid precursor
protein (APP) by b- and g-secretases results in increased pro-
duction of Ab, particularly the longer 42 amino acid form (Fig-
ure 5). The critical role of Ab production, self-aggregation, and
neurotoxicity in AD has been established from genetic studies
that identified mutations in APP and presenilin-1 (the enzymatic
component of the g-secretase protein complex) as the causes of
many cases of early-onset dominantly inherited AD, and from in-
vestigations of animal and cell culture models of AD (see Matt-
son, 2004; Hardy, 2006 for review). The mechanisms of neuronal
degeneration downstream of Ab involve membrane-associated
oxidative stress, perturbed Ca2+ homeostasis, impaired energy
metabolism, and possibly apoptosis, suggesting roles for mito-
chondrial alterations in the disease process.
Positron emission tomography (PET) measurements of radio-
labeled 2-deoxyglucose uptake into brain cells of living subjects
have demonstrated reduced energy metabolism in affected
brain regions of AD patients, and recent prospective imaging
studies suggest that the cellular energy deficit precedes cogni-
tive symptoms (Mosconi et al., 2008). Cytochrome c oxidase
activity is decreased in the brains of AD patients compared
with age-matched control subjects (Maurer et al., 2000). Neu-
rons that exhibit increased oxidative stress in AD also exhibit
damaged mitochondria and increased autophagy (Hirai et al.,
2001; Moreira et al., 2007). Studies of cybrid cells prepared by
fusion of platelets from AD patients and control subjects with
an immortal cell line have provided evidence for a widespread
defect in mitochondrial function characterized by reduced cyto-
chrome c oxidase activity and increased free radical production
(Swerdlow et al., 1997). The cause of the mitochondrial alter-
ations in cells of AD patients is unknown, but may involve aging
and disease-related increases in Ab levels, oxidative stress, and
reduced cellular energy availability.
Ab may promote neuronal mitochondrial dysfunction in neu-
rons in AD because exposure of cultured neurons to Ab results
in increased mitochondrial O2
$ production, decreased ATP
production, and increased mitochondrial Ca2+ uptake that can
trigger opening of the PTP and apoptosis (Hashimoto et al.,
2003). Ab impairs mitochondrial function by inducing membrane
lipid peroxidation and the production of 4-hydroxynonenal
(Bruce-Keller et al., 1998), a toxic aldehyde that can impair the
function of synapticmitochondria (Keller et al., 1997). In addition,
Ab can increase the hydrolysis of membrane sphingomyelin by
Figure 5. Involvement of Amyloidogenic APP Processing, Oxidative Stress, and Perturbed Cellular Ca2+ Homeostasis in Mitochondrial
Dysfunction in Alzheimer’s Disease
Amyloidogenic processing of APP involves sequential cleavages by b-secretase (BACE), which cleaves APP at the cell surface, and g-secretase, which cleaves
within the membrane-spanning domain of APP, resulting in the liberation of the amyloid b-peptide (Ab). Abmonomers interact to form oligomers, and during this
process Abmay interact with Fe2+ or Cu+ to generate H2O2 and OH$, thus resulting in membrane lipid peroxidation and the generation of 4-hydroxynonenal (HNE)
and ceramide. By impairing the function of plasma membrane ion-motive ATPases (Na+ and Ca2+ pumps) and glucose and glutamate transporters (not shown),
HNE promotes excessive Ca2+ influx through N-methyl-D-aspartate (NMDA) receptors and voltage-dependent Ca2+ channels (VDCC). Abmay also form Ca2+-
conducting pores in the plasma membrane. Excessive Ca2+ influx and release from ER stores may then result in excessive Ca2+ uptake into mitochondria and
impairment of their function. Alternatively, HNE and ceramide may diffuse to mitochondria and directly damage mitochondrial membranes. Abmay also be gen-
erated intracellularly in an endosomal/lysosomal compartment; intracellular Abmay interact with and damage mitochondrial membranes. In these ways, Abmay
impair mitochondrial ATP production and Ca2+ regulation, with adverse consequences for neuronal plasticity and survival.756 Neuron 60, December 11, 2008 ª2008 Elsevier Inc.
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(Cutler et al., 2004), thus triggering mitochondria-mediated neu-
ron death by a mechanism involving dephosphorylation of Akt,
BAD, and GSK-3b (Stoica et al., 2003). Ceramide alters mito-
chondrial Ca2+ homeostasis and triggers apoptosis by inducing
cyclin-dependent kinase-5-mediated phosphorylation of tau,
resulting in the clustering of mitochondria with the ER and
thereby increasing the mitochondrial uptake of Ca2+ released
from the ER (Darios et al., 2005). Abmay also act directly on mi-
tochondria by impairing electron transport (Manczak et al., 2006;
Veereshwarayya et al., 2006) and interacting with the mitochon-
drial protein Ab-binding alcohol dehydrogenase (ABAD), which
impairs the binding of NAD to ABAD (Lustbader et al., 2004). It
has also been suggested that APP is present in mitochondria
where it can be processed by Ab-generating presenilin-1/g-sec-
retase (Hansson et al., 2004) and by the mitochondrial protease
HtrA2, which generates a 161 amino acid nonamyloidogenic
C-terminal APP fragment (Park et al., 2006a). A remaining unan-
swered question is how Ab interacts with membrane lipids and
proteins to perturb mitochondrial function, but peptide oligomer-
ization and metal (Fe2+ and Cu+) generation of hydrogen perox-
ide are implicated (Mattson, 2004).
Mechanisms of mitochondrial dysfunction in AD that are in-
dependent of Ab have also been suggested. For example, pre-
senilin mutations may promote mitochondrial dysfunction by
perturbing ER Ca2+ handling, which in turn promotes synaptic
mitochondrial Ca2+ overload and can trigger apoptosis (Bez-
prozvanny and Mattson, 2008). Wild-type presenilin-1 may
function as a Ca2+ leak channel in the ER, and AD-causing
mutations impair this Ca2+-regulating function of presenilin-1.
It has also been shown that presenilin-1 mutations impair kine-
sin-based axonal transport (Pigino et al., 2003), suggesting
that presenilin-1 may influence the movement of mitochondria
to axon terminals. Increasing evidence also suggests a role for
mitochondrial alterations upstream of Ab and tau pathologies
in AD. Cytochrome c oxidase deficiency in neurons results in
decreased Ab accumulation and lower levels of oxidative
stress in a mouse model of AD (Fukui et al., 2007). Mitochon-
drial superoxide accumulation may contribute to the AD pro-
cess because APP mutant mice with reduced levels of MnSOD
exhibit worsening of behavioral deficits and dendritic pathol-
ogy (Esposito et al., 2006). Altogether, the available data iden-
tify several possible targets for therapeutic interventions that
stabilize mitochondria in AD, including b- and g-secretase in-
hibitors, antioxidants, mitochondrial membrane-stabilizing
agents, and agents that target Ca2+-regulating proteins. Exer-
cise, cognitive stimulation, and dietary energy restriction may
also protect mitochondria against AD-associated dysfunction
in part by increasing neurotrophic factor signaling (Arumugam
et al., 2006).
In order to better understand the roles of mitochondrial alter-
ations in AD, longitudinal studies of molecular, structural, and
functional aspects of mitochondria in neurons in animal models
of AD are needed. Parallel studies in which the effects of specific
manipulations of mitochondrial functions (ATP and ROS produc-
tion, Ca2+ handling, etc.) on Ab and tau pathologies and synaptic
plasticity are evaluated would help clarify if and how mitochon-
dria modify AD pathogenic processes.
Parkinson’s Disease
Evidence supports a major role for mitochondrial alterations in
Parkinson’s disease (PD), the most commonmovement disorder
(see Schapira, 2008 for review). Degeneration of dopaminergic
neurons in the substantia nigra underlies motor dysfunction in
PD, and the disease also involves degeneration of neurons in re-
gions of the brain controlling autonomic functions, cognition, and
mood (Braak et al., 2003). Neurons that degenerate in PD often
contain intracellular inclusions of the protein a-synuclein which
form the so-called Lewy bodies. The causes of sporadic cases
of PD are unknown, but decreased levels of mitochondrial com-
plex I activity are associated with the disease process (Swerdlow
et al., 1996). Complex I in PD has oxidatively damaged and mis-
assembled protein subunits (Keeney et al., 2006). In addition, the
environmental toxins rotenone andMPTP cause degeneration of
dopaminergic neurons and PD-like symptoms in animal models
by a mechanism involving selective inhibition of complex I (Ger-
lach et al., 1991), suggesting that complex I impairment may be
sufficient to cause the disease. Mitochondrial DNA deletions
have also been implicated in the degeneration of dopaminergic
neurons (Biskup and Moore, 2006), although whether mitochon-
drial DNA damage is pivotal for PD remains unknown.
Some cases of PD are inherited and have an early age of dis-
ease onset (see Bogaerts et al., 2008 for review). Mutations in
a-synuclein (PARK1), leucine-rich repeat kinase 2 (LRRK2)
(PARK8), and ubiquitin C-terminal hydrolase L1 (UCHL1)
(PARK5) cause PD that is inherited in an autosomal-dominant
manner, while mutations in Parkin (PARK2), DJ-1 (PARK7), and
PTEN-induced putative kinase 1 (PINK1) (PARK6) cause PD
when inherited from both parents (recessive mutations). Muta-
tions in the gene encoding the mitochondrial serine protease
HtrA2 (PARK13) have also been linked to PD in several families.
a-synuclein is located in presynaptic terminals where it may play
a role in dopaminergic signaling (Abeliovich et al., 2000). a-syn-
uclein is normally degraded by the ubiquitin-proteasome path-
way, and studies of cultured cells (Saha et al., 2000) and a family
with inherited PD caused by a triplication of the a-synuclein gene
(Singleton et al., 2003) suggest that even modest intracellular
accumulation of a-synuclein can result in the dysfunction and
degeneration of dopaminergic neurons (Figure 6).
Overexpression of wild-type a-synuclein in cultured cells re-
sults in the formation of a-synuclein-immunopositive inclusions,
increased levels of oxidative stress, and mitochondrial alter-
ations that are ameliorated by treatment with antioxidants (Hsu
et al., 2000). Inducible expression of mutant a-synuclein in
PC12 cells impairs proteasome activity and increases the vulner-
ability of the cells to mitochondria-mediated (PTP- and caspase-
3-dependent) apoptosis (Tanaka et al., 2001).Mitochondrial dys-
function and damage have been documented in brain cells of
a-synuclein mutant mice and Parkin-deficient mice (Stichel
et al., 2007). a-synuclein A53T mutant mice develop mitochon-
drial DNA damage and neuronal degeneration, and show
evidence for apoptosis of neocortical, brainstem, and motor
neurons (Martin et al., 2006). A proteomic analysis of brain tissue
samples from transgenic mice overexpressing A30P a-synuclein
revealed increased oxidative modification and impaired enzy-
matic activity of themetabolic proteins carbonic anhydrase 2, al-
pha-enolase, and lactate dehydrogenase 2 (Poon et al., 2005).Neuron 60, December 11, 2008 ª2008 Elsevier Inc. 757
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tions at the outer mitochondrial membrane or by accumulating
inside the mitochondria (Devi et al., 2008).
Parkin is a ubiquitin E3 ligase that associates with mitochon-
drial membranes and can protect mitochondria against apopto-
tic PTP opening and cytochrome c release (Darios et al., 2003).
Drosophila deficient in Parkin exhibit locomotor deficits due to
apoptotic death of muscle cells and reduced lifespan; mitochon-
drial abnormalities occur early in the process of muscle degener-
ation (Greene et al., 2003). A proteomic analysis of Parkin-
deficient mice revealed decreased levels of several subunits of
complexes I and IV, and striatal cells from the mice exhibited re-
duced mitochondrial respiratory capacity and decreased antiox-
idant capacity (Palacino et al., 2004). Parkin may directly interact
with DJ-1, and PDDJ-1mutants show a reduction in this interac-
tion, resulting in failure of Parkin to ubiquitinate and enhance the
degradation of mutant DJ-1 (Moore et al., 2005).
Cell fractionation and immunoultrastructural analysis showed
that DJ-1 is present in the mitochondrial intermembrane space
and in the matrix, and that PD-linked DJ-1 mutants are similarly
localized in mitochondria (Zhang et al., 2005). DJ-1 functions to
reduce mitochondrial oxidative stress, and recent findings sug-
gest that DJ-1 exhibits peroxiredoxin-like peroxidase activity
(Andres-Mateos et al., 2007). Oxidation of DJ-1 to form cyste-
ine-sulfinic acid at cysteine 106 results in mitochondrial localiza-
tion of DJ-1 and protection against cell death (Canet-Avile´s et al.,
2004). DJ-1 is also located in mitochondria in Drosophila neu-
rons, and Drosophila DJ-1 mutants exhibit locomotor dysfunc-
tion that is exacerbated by oxidative stress (Park et al., 2005).
Overexpressing a-synuclein or reducing levels of Parkin or
DJ-1 renders C. elegans vulnerable to mitochondrial complex I
inhibitors, but not direct oxidative insults (Ved et al., 2005), con-
sistent with mitochondrial impairment being a common mecha-
nism by which different familial PD mutations promote neuronal
degeneration.
PINK1 is a serine/threonine kinase located in mitochondria
where it may associate with outer and inner membranes.
PINK1 appears to play an important role in mitochondrial main-
tenance because depletion of PINK1 in cultured cells results in
abnormal mitochondrial morphology and membrane depolariza-
tion, and similar mitochondrial alterations are present in primary
cells from patients with PINK1 mutations (Exner et al., 2007). In-
activation of PINK1 in Drosophila results in degeneration of
dopaminergic neurons and muscle cells that is preceded by mi-
tochondrial enlargement and disintegration (Yang et al., 2006). In
Drosphila PINK1 is required for normal mitochondrial function,
and Parkin can rescue mitochondrial function in PINK1 mutants
(Clark et al., 2006; Park et al., 2006b). PINK1 may regulate mito-
chondrial biogenesis because it has been shown to interact with
proteins that control the processes of mitochondrial fission and
fusion; overexpression of PINK1 increases mitochondrial fission,
whereas depletion of PINK1 increases fusion (Yang et al., 2008).
Loss-of-function mutations of Drp1, a mitochondrial fission-pro-
moting protein, are largely lethal in a PINK1 or Parkin mutant
background, whereas cell degeneration and mitochondrial mor-
phological alterations caused by PINK1 and Parkin mutations
are suppressed by Drp1 (Poole et al., 2008). PINK1 may protect
mitochondria against oxidative stress by phosphorylating the
mitochondrial chaperone protein TRAP1 (Pridgeon et al., 2007).
Thus, mutations in several proteins that cause familial PD serve
important roles in the physiology and plasticity of mitochondria,
strongly suggesting a pivotal role for mitochondrial abnormalities
in PD.
The details of themolecular events bywhich a-synuclein accu-
mulation and mutations in Parkin, DJ-1, and PINK1 impair mito-
chondrial function and trigger dopaminergic neuron death
Figure 6. The Degeneration of Dopaminergic
Neurons in Parkinson’s Disease Involves Impaired
ETC Function, Proteasomal Overload,
and Excitotoxicity
Mitochondrial complex I activity is reduced in vulnerable
neurons in PD, likely as the result of a combination of nor-
mal aging, exposures to environmental toxins, and genetic
factors. The resulting ATP depletion and increased levels
of ROS render neurons vulnerable to excitotoxic Ca2+
overload. Mutations in genes that cause inherited PD
(a-synuclein, Parkin, DJ-1, PINK1, UCHL1, and LRRK2)
may adversely affect mitochondrial function either indi-
rectly or directly. Mutations of a-synuclein (or increased
amounts of wild-type a-synuclein caused by increased ex-
pression or decreased proteasomal degradation) results
in the formation of a-synuclein oligomers that may exacer-
bate ROS-mediated damage to mitochondrial mem-
branes and proteins. UCHL2 mutations may contribute
to proteasomal overload in PD. Parkin is a ubiquitin E3 li-
gase that plays important roles in removing damaged pro-
teins from neurons; this E3 ligase activity is reduced in PD,
resulting in excessive accumulation of damaged/neuro-
toxic proteins. Parkin may affect one or more proteins of
the PTP, thereby preventing cytochrome c release and ap-
optosis. DJ-1 is a mitochondrial protein that reduces ROS
and blocks PTP formation. PINK1 is important for the
maintenance of membrane potential and suppression of
oxidative stress. Thus, mutations in DJ-1 and PINK1 pro-
mote damage to mitochondria. E1, ubiquitin E1 ligase;
E2, ubiquitin E2 ligase; LRRK2, leucine-rich repeat kinase
2; UCHL1, ubiquitin C-terminal hydrolase L1.758 Neuron 60, December 11, 2008 ª2008 Elsevier Inc.
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actions with mitochondrial ETC proteins, Ca2+-regulating sys-
tems, Bcl-2 family proteins, and PTP proteins. Despite the lack
of a full understanding of molecular pathogenesis, the availability
of mitochondrial toxin-based and genetic mutation-based cell
culture and animal models of PD provide abundant opportunities
for preclinical screening of drugs and dietary and behavioral
interventions. Indeed, a range of promising agents (MAO inhibi-
tors, antiapoptotic agents, and creatine) are in transition from
bench to bedside (Schapira, 2008).
Huntington’s Disease
Huntington’s disease (HD), themost common inherited neurode-
generative disorder, is caused by expansions of CAG repeats in
the huntingtin gene resulting in polyglutamate repeats in the hun-
tingtin protein (Walker, 2007). Medium spiny neurons in the stria-
tum and cerebral cortical and brainstem neurons are among the
cell populations most severely affected in HD, resulting in char-
acteristic motor, cognitive/behavioral, and autonomic deficits.
Several adverse effects of mutant huntingtin on mitochondria
have been reported, including the following: impaired mitochon-
drial trafficking (Chang et al., 2006); reduced ATP levels in synap-
tic terminals (Orr et al., 2008); mitochondrial depolarization at
lower Ca loads as compared with mitochondria from controls
(Panov et al., 2002); increased sensitivity to Ca2+ overload and
NMDA receptor-mediated neuronal apoptosis (Fernandes
et al., 2007); enhanced sensitivity to Ca2+-induced decreases
in state 3 respiration and membrane potential (Milakovic et al.,
2006); and a decreased threshold for PTP opening and cyto-
chrome c release (Choo et al., 2004). Impaired mitochondrial
electron transport may also contribute to the pathogenesis of
HD because exposure of rodents to the succinate dehydroge-
nase inhibitor 3-nitropropionic acid results in selective damage
to striatal medium spiny neurons and motor dysfunction similar
to that of humans with HD (Brouillet et al., 2005).
Other findings suggest that mutant huntingtin can adversely
affect mitochondria by modifying gene transcription. For exam-
ple, mutant huntingtin represses the transcription of PGC-1a
by interacting with the promoter and interfering with the CREB-
dependent PGC-1a gene expression (Cui et al., 2006). Inhibition
of PGC-1a expression limits the ability of the vulnerable neurons
to adequately respond to energy demands in HD. Direct toxic
effects of mutant huntingtin on mitochondria and energy-depen-
dent neuronal processes such as axonal transport may worsen
when the protective function of PGC-1a is inhibited. Indeed,
crossbreeding of PGC-1a-deficient mice with HD knockin mice
leads to increased neurodegeneration of striatal neurons and
motor abnormalities in the HD mice (Cui et al., 2006). In a related
study, Weydt et al. (2006) reported reduced expression of PGC-
1a target genes in caudate nucleus of postmortem HD patient
brain tissues using microarray gene expression methods. Over-
expression of PGC-1a protects striatal neurons against mutant
huntingtin. The transcriptional activity of the proapoptotic pro-
tein p53 is increased by binding to mutant huntingtin, and levels
of p53 are increased in the brains of HD patients and huntingtin
mutant mice (Bae et al., 2005). Selective depletion or inhibition of
p53 preserves mitochondrial membrane potential, protects
cultured cells against mutant huntingtin-induced death, and
abrogates behavioral deficits in hungtingtin mutant mice. Drugs
that selectively inhibit p53 (Zhu et al., 2002) therefore have the
potential to prevent the death of neurons in HD.
Because individuals with HD can be identified by genetic
screening, it is possible to initiate treatments before they be-
come symptomatic, a fact that provides the opportunity to pre-
serve vulnerable neurons and thereby delay disease onset. In
this regard, several drugs in use for other disorders, including
the antiexcitotoxic agent tiagabine (Masuda et al., 2008), the
antidepressant paroxetine (Duan et al., 2004), and the histone
deacetylase inhibitor sodium butyrate (Ferrante et al., 2003),
have proved effective in animal models of HD and will hopefully
soon be tested in patients. Advances in molecular biology have
led to the development of small interfering RNAs (siRNAs) that
selectively suppress expression of mutant huntingtin and retard
the disease process in huntingtin mutant mice (DiFiglia et al.,
2007). Perhaps some day such approaches can be used in HD
patients.
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is characterized clinically by
progressive neuromuscular dysfunction resulting from degener-
ation of lower motor neurons (see Bromberg, 2002 for review).
While most cases of ALS are sporadic, the disease can be in-
herited as the result of mutations in Cu/Zn-SOD (SOD1/ALS1),
Alsin (ALS2), TDP-43, and other yet-to-be identified genes
(Gros-Louis et al., 2006; Sreedharan et al., 2008). Lines of trans-
genicmice expressing an ALSSOD1mutation provide a valuable
model of the human disease because they reliably develop pro-
gressive degeneration of lower motor neurons and die from the
disease (see Kato, 2008 for review). Several aspects of the phe-
notype of lower motor neurons suggest possible reasons why
they are selectively vulnerable in ALS (see Boille´e et al., 2006
for review). Motor neurons are the largest type of neuron with
very long (in some cases a meter or more in length), large-diam-
eter axons, resulting in both a high energy requirement and the
necessity for efficient axonal transport. As with other neurode-
generative disorders, considerable evidence suggests that mo-
tor neurons in ALS suffer from increased levels of oxidative
stress (Beal et al., 1997; Pedersen et al., 1998; Cutler et al.,
2002; Cai et al., 2005), perturbed cellular Ca2+ homeostasis in-
volving an excitotoxic component (Rothstein, 1995; Kruman
et al., 1999), cytoskeletal abnormalities (Binet and Meininger,
1988; Manetto et al., 1988), mitochondrial dysfunction (von Lew-
inski and Keller, 2005), and the triggering of apoptotic biochem-
ical cascades (Sathasivam et al., 2001).
Mitochondria are transported in axons and are present in rel-
atively high amounts in axon terminals of motor neurons where
they provide the ATP necessary to support the maintenance
and restoration of ion gradients during neuromuscular activity.
Ultrastructural analysis of neuromuscular junctions in tissue bi-
opsy samples from ALS patients revealed abnormalities in mito-
chondrial morphology (Atsumi, 1981). Mitochondrial dysfunction
and degeneration have been observed inmotor neurons in SOD1
mutant mice. At the onset of motor symptoms, there is amassive
degeneration of mitochondria in motor neurons that occurs long
before themotor neurons die (Kong and Xu, 1998). Other findings
suggest that mutant SOD1 impairs fast axonal transport,Neuron 60, December 11, 2008 ª2008 Elsevier Inc. 759
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(De Vos et al., 2007). Mutant Cu/Zn-SOD misfolds and self-
aggregates, and it has been reported that misfolded Cu/Zn-
SOD binds to mitochondrial membranes (Vande Velde et al.,
2008). The interaction of mutant Cu/Zn-SOD with mitochondria
may cause a shift in the redox potential, resulting in an increased
production of oxyradicals (Ferri et al., 2006). Impaired function of
Bcl-2 may also contribute to mitochondrial dysfunction in ALS
because mutant SOD1 proteins form aggregates that sequester
Bcl-2 in spinal cord cells (Pasinelli et al., 2004). A role for per-
turbed Cu metabolism in ALS is suggested by a study showing
that overexpression of the Cu chaperone for SOD1 in SOD1 mu-
tant ALS mice resulted in severe mitochondrial pathology, a dra-
matic acceleration of motor neuron degeneration, and death of
the mice (Son et al., 2007). Mutant SOD1 may not only have un-
toward effects on mitochondria in motor neurons, but may also
cause dysfunction of mitochondria in astrocytes, resulting in
increased oxyradical production that may adversely affect neu-
rons (Cassina et al., 2008).
Several treatments or genetic manipulations that prevent or
counteract mitochondrial impairment have been reported as ef-
fective in suppressing the disease process in SOD1 mice. Two
inhibitors ofmitochondrial PTP formation, cyclosporin A and nor-
triptyline, delayed disease onset and increased survival of ALS
mice (Keep et al., 2001; Wang et al., 2007). Dietary supplemen-
tation with creatine, which enhances cellular energy availability
and reduces oxidative stress, protected motor neurons and ex-
tended survival of SOD1 mutant mice (Klivenyi et al., 1999). De-
letion of the proapoptotic protein Bax protected motor neurons
from mutant SOD1-induced death, delayed disease onset, and
extended survival, but failed to prevent neuromuscular denerva-
tion and mitochondrial vacuolization (Gould et al., 2006). Such
preclinical findings suggest a therapeutic potential for interven-
tions that preserve or enhance mitochondrial energy metabo-
lism, reduce mitochondrial ROS production, stabilize mitochon-
drial membranes, or some combnation thereof.
Psychiatric Disorders
Evidence that patients with psychiatric disorders (depression, bi-
polar disorder, and schizophrenia) exhibit mitochondrial abnor-
malities at the structural, molecular, and functional levels has
been reviewed recently (Shao et al., 2008). There have been at
least 19 case reports of patients with mitochondrial disease pre-
senting with symptoms of a psychiatric disorder that in most
cases occurred prior to diagnosis of mitochondrial disease (Fat-
tal et al., 2006). Of these cases, five had major depressive disor-
der, eight had psychosis, one had bipolar disorder, three had an
anxiety disorder, and one had a major personality change. The
latter findings suggest the possibility that a mitochondrial deficit
is sufficient to trigger one or more psychiatric disorders. Mito-
chondrial deficits in idiopathic psychiatric disorders are sug-
gested from PET analysis of brain energy metabolism. Patients
with depression exhibit reduced glucose utilization in the pre-
frontal cortex, anterior cingulate gyrus, and caudate nucleus
(Videbech, 2000). The energy metabolism deficits in patients
with depression may be widespread, as suggested from data
demonstrating reduced mitochondrial ATP production rate and
increased mitochondrial DNA deletions in patients compared
with control subjects (Gardner et al., 2003). Patients with bipolar
disorder also exhibit impaired brain energy metabolism and
reductions in the levels of mitochondrial proteins involved in en-
ergy metabolism, and may also have increased mtDNA muta-
tions (Kato, 2007). Schizophrenia patients exhibit reduced com-
plex IV activity in the frontal cortex and caudate nucleus, which is
associated with increased emotional and cognitive impairment
(Prince et al., 2000). Alterations in the expression of genes en-
coding mitochondrial proteins in brain tissue samples from pa-
tients with bipolar disorder and schizophrenia have been docu-
mented (for example, see Iwamoto et al., 2005).
Thus far the data suggesting roles for mitochondrial alterations
in psychiatric disorders are correlations only, and it therefore re-
mains to be determined whether the alterations contribute to the
disease process or are epiphenomena. The development of
animal models of psychiatric disorders in which the effects of
genetic and pharmacological manipulations of mitochondrial
functions on the behavioral phenotype are examined would
shed light on the role of mitochondria in the disease process.
There have been several reports of improvement in the symp-
toms of psychiatric patients during treatment with coenzyme
Q10 (Onishi et al., 1997; Shinkai et al., 2000), suggesting a poten-
tial clinical benefit of mitochondria-directed treatments.
Future Directions
The information reviewed above reveals enabling and regulatory
roles for mitochondria in the function and plasticity of neurons,
and implicates mitochondrial dysfunction in the pathogenesis
of a range of neurological disorders. However, there remain large
gaps in our understanding of major aspects of mitochondrial
contributions to neuronal morphogenesis, function, and re-
sponses to physiological and pathological challenges. Ques-
tions that must be addressed in order to fully understand mito-
chondrial neurobiology include the following. (1) What are the
molecular mechanisms by which mitochondria respond to
changes in the activation state of major classes of neuronal sig-
nals, including neurotrophic factors, neurotransmitters, neuro-
peptides, and cytokines? (2) How do specific second messen-
gers (Ca2+, cyclic nucleotides, etc.), kinases, and transcription
factors affect mitochondrial energy metabolism and Ca2+ and
redox signaling? (3) What are the mechanisms of and roles for
mitochondrial dynamics in the development and plasticity of
neuronal circuitry? (4) Does mitochondrial dysfunction play
only a contributory role to neurodegenerative disorders down-
stream of the major pathogenic abnormality, or are mitochon-
drial alterations early seminal events? (5) Can neuronal dysfunc-
tion and degeneration be prevented by interventions that
sustain mitochondrial function? (6) Can synaptic plasticity and
neurological functions (learning and memory, motor function,
emotional health) be enhanced by interventions that target mito-
chondria? (7) How do changes in mitochondria mediate the
effects of environmental factors that either improve (exercise,
dietary energy restriction, and cognitive stimulation) or worsen
(diabetes, overeating, and a sedentary lifestyle) brain health, if
at all? The molecular and functional complexity of mitochondria,
and their ability to fuse, divide, and move within neurons, por-
tends new revelations regarding their roles in neuroplasticity
and disease.760 Neuron 60, December 11, 2008 ª2008 Elsevier Inc.
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